-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson rose 0.4% in early Friday trading. The company received approval from the US Food and Drug Administration: its RYBREVANT FasPro can be used in combination with lazertinib for first-line treatment of EGFR mutated non-small cell lung cancer to achieve 5-minute subcutaneous administration.

Zhitongcaijing·12/19/2025 16:17:09
Listen to the news
Johnson & Johnson rose 0.4% in early Friday trading. The company received approval from the US Food and Drug Administration: its RYBREVANT FasPro can be used in combination with lazertinib for first-line treatment of EGFR mutated non-small cell lung cancer to achieve 5-minute subcutaneous administration.